Table 2.
| Crizotinib Treated Group 1 (CTG1) | Crizotinib Treated Group 2 (CTG2) | Non-Crizotinib Treated Group (NCTG) | |
|---|---|---|---|
|
|
|||
| No. patients | 32 | 19 | 19 |
|
| |||
| Age (Median) | 54 yrs | 60 yrs | 63 yrs |
| Range | 33 – 69 | 35 – 81 | 43 – 78 |
|
| |||
| Cancer | |||
| Non-small cell lung cancer | 31(97%) | 19 (100%) | 19 (100%) |
| Colorectal cancer | 1 (3%) | 0 (0%) | 1 (5%) |
|
| |||
| Molecular Status | |||
| ALK rearranged | 26 (82%) | 17 (90%) | 2 (11%) |
| ROS1 fusion gene | 2 (6%) | 1 (5%) | 0 (0%) |
| MET amplification | 1 (3%) | 1 (5%) | 0 (0%) |
| EGFR mutation | 1 (3%) | 0 (0%) | 5 (26%) |
| KRAS mutation | 1 (3%) | 0 (0%) | 3 (16%) |
| Undefined/Other | 1 (3%) | 0 (0%) | 9 (47%) |
|
| |||
| Current Therapy | |||
| Crizotinib | 32 (100%) | 19 (100%) | 0 (0%) |
| Median duration | 6.3 months | 7.3 months | - |